Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

242.84 -2.65 (-1.08%)
Official Closing Price Updated: 7:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
3 Top S&P 500 Stock Market Gainers Today: Energy Dominates As Adobe Dives
Energy and commodity plays were top performers Wednesday. 
Via Investor's Business Daily
Markets Fall Amid Rising Oil Prices
U.S. indices finished lower Wednesday as investors continue to weigh the Federal Reserve tapering outlook, inflation concerns and the Russia-Ukraine war. Oil prices have also... 
Via Benzinga
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. 
Via InvestorPlace
Ominous Death Cross Forms On ResMed's Chart
If history is any guide, there may be trouble ahead for shares of ResMed (NYSE:RMD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Expert Ratings For ResMed
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: ResMed Q2 Earnings
ResMed (NYSE:RMD) reported its Q2 earnings results on Thursday, January 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ResMed missed... 
Via Benzinga
Earnings Scheduled For January 27, 2022
Companies Reporting Before The Bell • SAP (NYSE:SAP) is estimated to report quarterly earnings at $1.87 per share on revenue of $9.10 billion. •... 
Via Benzinga
Sleep Apnea Device Maker Resmed Sees Improved Relative Strength
Resmed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •... 
Via Benzinga
ResMed's Return on Invested Capital Overview
According to Benzinga Pro, during Q2, ResMed (NYSE:RMD) earned $201.75 million, a 0.91% increase from the preceding quarter. ResMed's sales decreased to $894.87 million, a 1.01%... 
Via Benzinga
The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
ResMed Q2 Earnings Highlights: Supply Chain Constraints, Unlimited Demand Due To Competitor Recall
ResMed Inc (NYSE: RMD) revealed a 13% Y/Y jump in Q2 FY22 revenue to $894.9 million, missing the consensus of $935.25 million. The growth was below analyst expectations... 
Via Benzinga
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview: ResMed
ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-01-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the... 
Via Benzinga
This Company Just Made a Possibly Lucrative Acquisition — What's Next?
Photo by Ccfb on Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The global... 
Via Benzinga
What 4 Analyst Ratings Have To Say About ResMed
Within the last quarter, ResMed (NYSE:RMD) has observed the following analyst ... 
Via Benzinga
Take Action To Unlock Supply Chain Disruption Issues
Businesses are grappling with supply chain disruption. And beating this challenge requires leaders to take decisive action right now. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 13, 2022
Upgrades According to Morgan Stanley, the prior rating for SunPower Corp (NASDAQ: 
Via Benzinga
4 Low-Beta Stocks To Buy For A Volatile Market
Global economic uncertainty, inflationary pressure, a disappointing jobs report, and concerns around the COVID-19 Omicron variant are fostering market volatility. So, against this backdrop, we think it... 
Via Talk Markets
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX: 
Via Benzinga
Notable Resmed Insider Trades $2.9M In Company Stock
Robert Douglas President And Chief Operating Officer, Resmed Inc., COO at Resmed (NYSE:RMD), made a large buy and sell of company shares on November 15, according to a new SEC... 
Via Benzinga
CNBC's Final Trades: Fiserv, ResMed, Monster Beverage And This Semiconductor Company
On CNBC’s “Halftime Report Fina... 
Via Benzinga
Global Home Medical Equipment Market Size Is Estimated To Reach $56 Billion By 2027
Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – Over the last few years, and with the ‘help’ of the pandemic, home health care medical equipment industry has surged. Home... 
Via FinancialNewsMedia
ResMed (RMD) Q1 2022 Earnings Call Transcript
RMD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
3 Leading Healthcare Stocks to Buy in 2021 and Beyond
Three healthcare stocks that have momentum on their side and are good buys right now. 
Via The Motley Fool
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Consistency is the main attraction for these companies. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback